clazosentan

endothelin A receptor antagonist used for cerebral vasospasm; structure in first source;

Also Known As:

AXV 034; AXV 343434; AXV-034; AXV-034343; AXV-343434; AXV343434; Ro 61-1790; Ro-61-1790; VML 588; VML-588; VML588; N-(6-(2-Hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-(1H-tetrazol-5-yl)pyridin-4-yl)pyrimidin-4-yl)-5-methylpyridine-2-sulfonamide

Networked: 80 relevant articles (10 outcomes, 49 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Macdonald, R Loch: 31 articles (01/2022 - 11/2008)
2.	Ibrahim, George M: 10 articles (03/2019 - 01/2012)
3.	Mayer, Stephan A: 8 articles (05/2020 - 07/2011)
4.	Raabe, Andreas: 8 articles (01/2013 - 06/2005)
5.	Ayling, Oliver G S: 6 articles (01/2022 - 09/2015)
6.	Eagles, Matthew E: 6 articles (01/2022 - 01/2018)
7.	Ilodigwe, Don: 6 articles (07/2013 - 10/2010)
8.	Marr, Angelina: 5 articles (05/2020 - 07/2011)
9.	Roux, Sébastien: 5 articles (05/2020 - 07/2011)
10.	Higashida, Randall T: 5 articles (10/2019 - 07/2011)

Related Diseases

1.	Intracranial Vasospasm 07/01/2005 - "In Part A, treatment with clazosentan resulted in a reduced incidence of angiographically evident cerebral vasospasm (40% compared with 88% of patients, p = 0.008). " 12/01/2023 - "Databases were systematically searched for randomized controlled trials directly comparing the use of clazosentan and placebo for the treatment of cerebral vasospasm after aSAH. " 08/09/2023 - "In double-blind, placebo-controlled phase 3 studies, clazosentan reduces cerebral vasospasm-related morbidity and all-cause mortality in patients with aSAH. " 03/01/2019 - "Trials of the effectiveness of clazosentan in treating cerebral vasospasm after aSAH were studied. " 01/01/2017 - "In a dose-finding trial (CONSCIOUS-1) conducted in Israel, Europe, and North America, clazosentan (1, 5, and 15 mg/h) significantly reduced the incidence of cerebral vasospasm, but its efficacy in Japanese and Korean patients was unknown. "
2.	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 01/01/2022 - "The REVERSE study (REversal of Vasospasm with clazosEntan post-aneuRysmal Subarachnoid hEmorrhage) was a prospective multicenter open-label pilot study of adult patients with aneurysmal subarachnoid hemorrhage who received intravenous clazosentan after developing moderate to severe angiographic vasospasm. " 03/01/2019 - "Clazosentan for Aneurysmal Subarachnoid Hemorrhage: An Updated Meta-Analysis with Trial Sequential Analysis." 11/01/2018 - "Different Doses of Clazosentan for Aneurismal Subarachnoid Hemorrhage: A Meta-Analysis of Randomized Controlled Trials." 07/01/2013 - "Dissociation of vasospasm-related morbidity and outcomes in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: a meta-analysis of randomized controlled trials." 01/01/2013 - "We report here results of a randomized, double-blind, placebo-controlled study ( http://www.ClinicalTrials.gov , NCT00558311) that investigated the effect of clazosentan (5 mg/h, n = 768) or placebo (n = 389) administered for up to 14 days in patients with aneurysmal subarachnoid hemorrhage (SAH) repaired by surgical clipping. "
3.	Cerebral Infarction 07/01/2013 - "The objective of this meta-analysis was to determine whether clazosentan treatment after aneurysmal SAH significantly reduced the incidence of DINDs and delayed cerebral infarctions and improved outcomes. " 03/01/2019 - "We found 10-15 mg/h of clazosentan administration was associated with lower rates of vasospasm and new cerebral infarctions compared with 5 mg/h. " 11/01/2018 - "The objective of this meta-analysis was to determine whether different doses of clazosentan treatment significantly reduced the incidence of delayed ischemic neurological deficits (DINDs) and new cerebral infarction (NCI). " 01/01/2017 - "The occurrence of cerebral infarction due to vasospasm was 20.8% in the placebo group (95% CI 10.8-34.1), 3.8% in the 5 mg/h clazosentan group (95% CI 0.5-13.2), and 4.2% in the 10 mg/h clazosentan group (95% CI 0.5-14.3), indicating that clazosentan significantly reduced the occurrence of cerebral infarctions caused by vasospasm (placebo vs. 5 mg/h clazosentan, p = 0.0151; placebo vs. 10 mg/h clazosentan, p = 0.0165). " 07/01/2013 - "The results of the present meta-analysis show that treatment with clazosentan after aneurysmal SAH significantly reduced the incidence of the vasospasm-related DINDs and delayed cerebral infarctions, but did not improve poor neurological outcomes in patients with aneurysmal SAH. "
4.	Infarction (Infarctions) 07/01/2005 - "The incidence of new infarctions was 15% in the clazosentan group and 44% in the placebo group (p = 0.130). " 03/18/2020 - "The selective ERA clazosentan has been shown to be effective in preventing cerebral vasospasm and delaying ischemic neurological deficits and new infarcts. " 12/01/1999 - "In this study we assessed the impact of ET-1 on perfusion and infarct volume in a focal model of cerebral ischemia by use of the selective ET(A) receptor antagonist Ro 61-1790 (affinity for ET(A) receptor 1000 fold greater than ETB receptor). " 01/01/2011 - "Clazosentan: prevention of cerebral vasospasm and the potential to overcome infarction." 01/01/2022 - "We performed a post hoc analysis of the "clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage" trial data set. "
5.	Brain Ischemia (Cerebral Ischemia) 12/20/2022 - "The REACT study: design of a randomized phase 3 trial to assess the efficacy and safety of clazosentan for preventing deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage." 12/01/1999 - "In this study we assessed the impact of ET-1 on perfusion and infarct volume in a focal model of cerebral ischemia by use of the selective ET(A) receptor antagonist Ro 61-1790 (affinity for ET(A) receptor 1000 fold greater than ETB receptor). " 03/01/2000 - "Administration of selective endothelin receptor type A antagonist Ro 61-1790 does not improve outcome in focal cerebral ischemia in cat." 01/01/2023 - "The endothelin receptor antagonist (ERA) clazosentan is being investigated for the medical prevention of cerebral vasospasm and associated complications, such as delayed cerebral ischemia (DCI), after aneurysmal subarachnoid hemorrhage (aSAH). " 02/01/2015 - "MEK1/2 inhibitor U0126 but not endothelin receptor antagonist clazosentan reduces upregulation of cerebrovascular contractile receptors and delayed cerebral ischemia, and improves outcome after subarachnoid hemorrhage in rats."

Related Drugs and Biologics

1.	Endothelin Receptor Antagonists
2.	Magnesium
3.	Nicardipine (Dagan)
4.	fasudil (AT 877)
5.	Endothelin A Receptor
6.	clazosentan
7.	Endothelins (Endothelin)
8.	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
9.	Endothelin Receptors (Endothelin Receptor)
10.	Nimodipine (Modus)

Related Therapies and Procedures

1.	Therapeutics
2.	Catheters
3.	Lasers (Laser)
4.	Intravenous Injections